CellFE Announces May 2024 Conference Presentations
CellFE announced today an upcoming presentation by CSO Todd Sulchek, PhD, at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, taking place May 7-11, 2024 in Baltimore, MD.
News
Categories
13 Results for ""
CellFE secures $22 million in Series A financing to advance microfluidics-based cellular engineering platform
CellFE announced the completion of a $22 million Series A financing led by M Ventures, with participation from Great Point Ventures, Riverine Ventures and its existing investors.
Endpoints News: CellFE raises $22M Series A to advance a new cell therapy manufacturing idea
Exclusive: The California-based startup CellFE has raised a $22 million Series A to advance a new approach to making cell therapies with microfluidics.
CellFE unveils research scale microfluidics-based cell engineering platform at BIO2022
The BIO International Convention (BIO) returns to in person meetings in San Diego, CA June 13-16 and CellFE will be there to present the…
CEO and Co-Founder Alla Zamarayeva presents in the Startup Showcase session at the ASGCT Annual
CEO and Co-Founder Alla Zamarayeva PhD presented recently at the Startup Showcase at the ASGCT 25th Annual Conference.
CellFE Co-Founder Joins 10 Women-led Companies in Springboard Enterprise’s 2022 Innovation Bootcamp
Alla Zamarayeva, Co-Founder and CEO, has joined 10 women-led companies to participate in Springboard Enterprise’s 2022 Life Sciences Innovation Bootcamp.
CellFE platform enables microfluidic Transfection of mRNA into T cells and HSPCs
CellFE, a microfluidics-based biotech startup based out of Alameda, CA, has recently had an article published in Scientific Reports.
CellFE to Present Multiple Posters at the American Society for Gene & Cell Therapy (ASGCT) 24th Annual Meeting
CellFE will be presenting two posters at the American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting next week occurring from May 11-14.
CellFE Presents at International Society for Cell & Gene Therapy (ISCT) ‘21
CellFE will be presenting a poster at the International Society of Gene and Cell Therapy (ISCT) Annual Meeting next week with a poster on Transfecting αβ T Cells with CRISPR-Cas9 RNP via microlfuidic method.
CellFE co-founder Todd Sulchek, PhD presented at Cellicon Valley ‘21
Todd Sulchek, PhD, Co-founder of CellFE and Head of the Sulchek BioMEMS & Biomechanics Lab at Georgia Tech, will be participating as a speaker…
CellFE’s platform enables efficient multiplex CRISPR-Cas9 editing to engineer T cells
Managing toxicity and specificity of cell therapies relies on complex gene-editing mechanisms, requiring co-delivery of multiple gene-editing molecules.
CellFE Closes Series Seed Funding Round
CellFE announced it has raised $3.6 million in an initial Series Seed, co-led by Cota Capital and Dynamk Capital, and joined by Embark Ventures.